1. Home
  2. CRGX vs EMO Comparison

CRGX vs EMO Comparison

Compare CRGX & EMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRGX
  • EMO
  • Stock Information
  • Founded
  • CRGX 2021
  • EMO 2011
  • Country
  • CRGX United States
  • EMO United States
  • Employees
  • CRGX N/A
  • EMO N/A
  • Industry
  • CRGX
  • EMO Investment Managers
  • Sector
  • CRGX
  • EMO Finance
  • Exchange
  • CRGX Nasdaq
  • EMO Nasdaq
  • Market Cap
  • CRGX 621.4M
  • EMO 599.1M
  • IPO Year
  • CRGX 2023
  • EMO N/A
  • Fundamental
  • Price
  • CRGX $13.84
  • EMO $51.00
  • Analyst Decision
  • CRGX Strong Buy
  • EMO
  • Analyst Count
  • CRGX 6
  • EMO 0
  • Target Price
  • CRGX $31.80
  • EMO N/A
  • AVG Volume (30 Days)
  • CRGX 228.3K
  • EMO 27.1K
  • Earning Date
  • CRGX 03-20-2025
  • EMO 01-01-0001
  • Dividend Yield
  • CRGX N/A
  • EMO 6.70%
  • EPS Growth
  • CRGX N/A
  • EMO N/A
  • EPS
  • CRGX N/A
  • EMO N/A
  • Revenue
  • CRGX N/A
  • EMO N/A
  • Revenue This Year
  • CRGX N/A
  • EMO N/A
  • Revenue Next Year
  • CRGX N/A
  • EMO N/A
  • P/E Ratio
  • CRGX N/A
  • EMO N/A
  • Revenue Growth
  • CRGX N/A
  • EMO N/A
  • 52 Week Low
  • CRGX $10.91
  • EMO $26.42
  • 52 Week High
  • CRGX $33.92
  • EMO $40.17
  • Technical
  • Relative Strength Index (RSI)
  • CRGX 49.08
  • EMO 74.09
  • Support Level
  • CRGX $10.91
  • EMO $49.02
  • Resistance Level
  • CRGX $15.75
  • EMO $51.87
  • Average True Range (ATR)
  • CRGX 1.14
  • EMO 0.91
  • MACD
  • CRGX 0.13
  • EMO 0.45
  • Stochastic Oscillator
  • CRGX 59.55
  • EMO 84.49

About CRGX CARGO Therapeutics Inc.

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.

About EMO ClearBridge Energy Midstream Opportunity Fund Inc.

ClearBridge Energy Midstream Opportunity Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide long-term investors with a high level of total return with an emphasis on cash distributions.

Share on Social Networks: